Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 4 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neurofibromatosis 2 1

Interventions

pembrolizumab 1032 Carboplatin 969 Paclitaxel 942 Gemcitabine 799 Cisplatin 755 Docetaxel 698 Bevacizumab 638 Nivolumab 520 Pemetrexed 507 Capecitabine 475 Cyclophosphamide 471 Fluorouracil 425 Dexamethasone 410 Rituximab 391 Oxaliplatin 352 Injections 345 Trastuzumab 313 atezolizumab 311 Cetuximab 291 Leucovorin 289 Irinotecan 271 130-nm albumin-bound paclitaxel 256 Prednisone 251 Ipilimumab 244 Doxorubicin 241 Lenalidomide 231 Fulvestrant 226 fludarabine 217 durvalumab 211 Erlotinib Hydrochloride 196

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × HDAC-42 × Clear all

NCT05130866 2025-10-07

POPLAR-NF2

Recursion Pharmaceuticals Inc.

Phase 2/3 Terminated

Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡